Codexis, Inc. (NASDAQ:CDXS – Get Free Report) CEO Alison Moore sold 10,651 shares of the stock in a transaction on Monday, November 16th. The shares were sold at an average price of $1.14, for a total transaction of $12,142.14. Following the completion of the sale, the chief executive officer directly owned 233,520 shares of the company’s stock, valued at approximately $266,212.80. This trade represents a 4.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Alison Moore also recently made the following trade(s):
- On Monday, October 12th, Alison Moore sold 6,335 shares of Codexis stock. The stock was sold at an average price of $1.36, for a total transaction of $8,615.60.
Codexis Stock Performance
NASDAQ:CDXS opened at $1.15 on Thursday. The firm’s 50-day moving average is $1.27 and its 200-day moving average is $1.78. The company has a market cap of $126.04 million, a price-to-earnings ratio of -5.75 and a beta of 2.38. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.99 and a current ratio of 2.81. Codexis, Inc. has a 52-week low of $0.90 and a 52-week high of $2.98.
Codexis (NASDAQ:CDXS – Get Free Report) last released its earnings results on Thursday, November 12th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.02. Codexis had a negative net margin of 21.77% and a negative return on equity of 43.24%. The business had revenue of $19.26 million during the quarter, compared to analysts’ expectations of $18.72 million. Equities research analysts anticipate that Codexis, Inc. will post -0.37 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the company. Wall Street Zen upgraded Codexis from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. Piper Sandler lowered their price objective on Codexis from $9.00 to $8.00 and set an “overweight” rating on the stock in a research report on Monday, August 17th. Stephens restated an “overweight” rating and issued a $5.00 target price on shares of Codexis in a research note on Monday. Benchmark restated a “hold” rating on shares of Codexis in a research note on Thursday, August 20th. Finally, Weiss Ratings raised Codexis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 23rd. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $6.00.
Get Our Latest Research Report on Codexis
Institutional Investors Weigh In On Codexis
A number of institutional investors have recently added to or reduced their stakes in the stock. EP Wealth Advisors LLC bought a new stake in shares of Codexis in the 2nd quarter valued at approximately $35,000. Corient Private Wealth LP bought a new position in shares of Codexis during the 2nd quarter worth approximately $37,000. Simplicity Wealth LLC bought a new position in shares of Codexis during the 2nd quarter worth approximately $39,000. The Manufacturers Life Insurance Company bought a new position in shares of Codexis during the 2nd quarter worth approximately $57,000. Finally, GSA Capital Partners LLP bought a new position in shares of Codexis during the 2nd quarter worth approximately $94,000. 78.54% of the stock is owned by institutional investors and hedge funds.
About Codexis
Codexis, Inc. is a biotechnology company that develops engineered enzymes for pharmaceutical and other manufacturing applications. Founded in 2002 and based in Redwood City, California, the company uses its protein-engineering platform, CodeEvolver, to design enzymes with properties suited to specific production processes. Codexis supplies enzymes and related development services for the manufacture of small-molecule drugs and other products. It also develops its ECO Synthesis platform, which uses enzymes to support the production of oligonucleotide therapeutics, including RNA-based medicines.
Recommended Stories
- Five stocks we like better than Codexis
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.
